SureTrader SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 1/22/2017 12:03:20 AM - Followers: 181 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Amended Statement of Ownership (sc 13g/a) 01/10/2017 04:17:49 PM
CVM News: Amended Statement of Ownership (sc 13g/a) 01/10/2017 02:06:24 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/03/2017 10:47:42 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/03/2017 10:31:07 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 01/03/2017 10:13:59 AM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#10198   So, I looked back at my verbiage... learning curve 01/22/17 12:03:20 AM
#10197   I was a bit, but at same time serious... learning curve 01/21/17 11:56:12 PM
#10196   Ok My neurons were not connected in a way lightrock 01/21/17 01:58:25 PM
#10195   St. Maarten is great and the weather is Foxwoods Man 01/21/17 07:35:05 AM
#10194   I will just assume that you are goofing Foxwoods Man 01/21/17 07:30:20 AM
#10193   Hard to learn much when given any outcome, pijoe 01/21/17 05:50:38 AM
#10192   How can it be postponed AGAIN if it learning curve 01/20/17 11:45:14 PM
#10191   I agree, but concept is interesting.... learning curve 01/20/17 11:41:21 PM
#10190   Forget everything else. How is st martin.. Investing pijoe 01/20/17 07:56:16 PM
#10189   I don't believe the FDA would place a trickledownfacists 01/20/17 07:38:31 PM
#10188   Please explain lightrock 01/20/17 06:01:09 PM
#10187   Does anyone know if the FDA sought and received sea alice 01/20/17 05:17:09 PM
#10186   Was thinking about this scenario. sea alice 01/20/17 05:12:39 PM
#10185   Let me put this so you MAYBE can Foxwoods Man 01/20/17 03:58:00 PM
#10184   So what exactly did you say in your learning curve 01/20/17 03:45:03 PM
#10183   Arbitration trial was not postponed...not an opinion Foxwoods Man 01/20/17 03:17:29 PM
#10182   Does any one here still think CVM can ducruacuteo11 01/20/17 01:55:30 PM
#10181   Ok captain obvious...it looks like you figured out learning curve 01/20/17 01:34:41 PM
#10180   Ok, thanks. I guess that means there should PlanTrader 01/20/17 01:18:10 PM
#10179   It started 3 years ago. The trial trickledownfacists 01/20/17 01:15:04 PM
#10178   Some friends of mine were in an arbitration PlanTrader 01/20/17 01:12:29 PM
#10177   If you took the time to actually read Foxwoods Man 01/20/17 10:28:03 AM
#10176   The trial is underway. trickledownfacists 01/20/17 10:14:18 AM
#10175   Really? Why? http://investorshub.advfn.com/boards/read_msg.aspx?message_id=1253 learning curve 01/20/17 10:12:21 AM
#10174   Really? I find this interesting...http://investorshub.advfn.com/boards/read_msg. learning curve 01/20/17 10:11:30 AM
#10173   Yeah I don't think that's the case. trickledownfacists 01/20/17 09:18:22 AM
#10172   I seem to have missed the fact that Foxwoods Man 01/20/17 06:43:26 AM
#10171   Actually the arbitrator decides who the victim is. learning curve 01/20/17 01:10:48 AM
#10170   It's not that CVM can't reply to what sinity 01/19/17 11:51:31 PM
#10169   On a side note; literally the side of learning curve 01/19/17 10:47:36 PM
#10168   It could be related to inventiv, but Cvm learning curve 01/19/17 10:43:30 PM
#10167   Wouldn't the FDA canceling multikine be directly related sinity 01/19/17 04:16:56 PM
#10166   Exactly! He could have said "my hands are Kami_ss 01/19/17 09:36:38 AM
#10165   What is he supposed to say? His hands trickledownfacists 01/19/17 09:16:47 AM
#10164   Going on 4 months with FDA partial hold steve2150 01/19/17 08:18:40 AM
#10163   Lol. Am I looking to much into it....or learning curve 01/19/17 01:35:09 AM
#10162   Just shorts covering. They need to take profits, KatCat 01/17/17 07:54:29 PM
#10161   man I hope you are correct about that. renaissance1 01/16/17 08:38:05 PM
#10160   Call me crazy but I bet we hear trickledownfacists 01/16/17 05:38:27 PM
#10159   i.e., I do much better when I do lightrock 01/15/17 03:13:27 PM
#10157   ballpark the pattern is about 2 months (hip shot) lightrock 01/15/17 02:22:45 PM
#10156   For fun: why do nfl teams protect their learning curve 01/15/17 01:30:18 AM
#10155   For fun.... learning curve 01/15/17 12:26:11 AM
#10154   .08333 is actually incorrect becuase the deduction of learning curve 01/14/17 11:21:19 PM
#10153   Wasn't telling you. Giving an opinion to anybody learning curve 01/14/17 11:15:04 PM
#10152   Hey, my sig line used to be "My Foxwoods Man 01/14/17 07:43:59 AM
#10151   Now you tell me. ducruacuteo11 01/14/17 12:51:19 AM
#10150   I don't think that is a good gambling strategy. learning curve 01/14/17 12:01:05 AM
#10149   Don't see any rise in penny just yet. ducruacuteo11 01/13/17 06:18:28 PM
#10148   WoW! Nice stash. Here's rooting for you...and us Foxwoods Man 01/13/17 03:04:53 PM
PostSubject